Medindia LOGIN REGISTER
Medindia
Advertisement

Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials

Monday, November 19, 2007 General News
Advertisement
BEIJING, Nov. 19 Sinovac Biotech Ltd. (Amex: SVA),a leading provider of biopharmaceutical products in China, today announced anupdate on the clinical trials for its pandemic influenza vaccines. Sinovacreceived approval in April 2007 from the China State Food and DrugAdministration (SFDA) to commence Phase Ib and II trials of its pandemicinfluenza (H5N1) whole viron inactivated vaccine and Phase I and II trials ofits pandemic influenza (H5N1) split vaccine.
Advertisement

In the pandemic influenza whole viron vaccine Phase II trial, a total of402 enrolled volunteers from 18 to 60 years old were vaccinated with doses of5ug, 10ug or 15ug. In accordance with the Phase II trial protocol, all of thevolunteers were vaccinated with two doses and followed for an observationperiod. There were no serious adverse events.
Advertisement

In the Phase I and Phase II trials for the split pandemic influenzavaccine, 160 volunteers from 3 to 70 years old, sorted into four different agegroups, were enrolled. The volunteers received doses of 5ug, 10ug, 15ug or30ug and were followed for an observation period. There were no seriousadverse events.

Separately, Sinovac's external auditors are currently reviewing theCompany's third quarter financial results, which the Company plans to disclosethereafter. Pertaining to the Annual General Meeting of Shareholdersoriginally scheduled for August 2007, the Company did not receive at that timesufficient shareholder votes, given the geographical nature of itsshareholders, to achieve a quorum, as per its corporate by-laws. Sinovac isdiligently working to reschedule its Annual General Meeting.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccinesinclude Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) andAnflu(TM) (influenza). Sinovac is currently developing human vaccines againstthe H5N1 strain of pandemic influenza, and Japanese encephalitis. Additionalinformation about Sinovac is available on its website, http://www.sinovac.com .To be added to our distribution list, please email: [email protected] .

Safe Harbor Statement

This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Contact Information: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: [email protected] Investors/Media: Stephanie Carrington/ Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: [email protected] [email protected]

SOURCE Sinovac Biotech Ltd.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close